Market Crash 2020: The Next Drop Will Be Much Worse

Stock markets remain shaky despite the dramatic rebound following the March crash. However, a sequel could be worse. Only the Trillium Therapeutics stock seems to be defying the pandemic. Analysts see explosive growth down the road.

Watch for the Warning Signs Stock Market Prices Trends 3d Illustration

Image source: Getty Images

Wall Street and the Toronto Stock Exchange were forced to pause trading when COVID-19 pounced on the investing world. Three times in eight days in mid-March 2020, stock exchanges in the U.S. and Canada had to implement a Level 1 market-wide circuit breaker.

Circuit breakers come into play when steep selloffs are happening in the stock market. It also means that trading will stop to soften the impact of a market crash. COVID-19 did the unthinkable. The Bank of Canada and the U.S. Federal Reserve, and other global central banks announced coordinated actions to enhance liquidity.

Fortunately, it wasn’t the end game because the market stormed back dramatically. As of September 21, 2020, the TSX is losing by only 1.34%. Investors stayed the course after the onslaught. However, fears are back. If the market crashes again, the drop could be much more.

Rebound after the bloodbath

It was a bloodbath for the TSX that saw the biggest one-day drop since the 1987 crash. On March12, 2020, the index fell 12.34% to 12, 508.50. Including the shutdowns, the TSX lost $21 billion in value. The slumping oil prices doubled the hit in Canada’s stock market.

Since the close of March 2020, the finished higher every month until August 31, 2020. This month’s closing is hard to predict, although September has the dubious record of being the worst month for stock markets. However, there are indicators a market crash is inevitable in the second half of the year.

The ending of stimulus packages is likely to result in higher consumer debt, defaults in mortgages and other loans. Canada, however, is introducing a new set of emergency income-support measures to shore up the economy. The recovery should be swift or else the country might run out of firepower.

Defying the pandemic

A $1.97 billion Canada-based biotechnology company is defying the impact of the pandemic. Trillium Therapeutics (TSX:TRIL)(NASDAQ:TRIL) is not one of the firms conducting clinical trials for a coronavirus vaccine, yet the stock is 1,415.04% year-to-date.

Had you invested $10,000 in the biotech stock on December 31, 2019, your money would be worth $151,503.76 today. Trillium specializes in clinical-stage immuno-oncology treatments. The biotech’s pre-clinical programs and therapies focus on treating cancer.

Trillium is getting a big lift from giants in the healthcare industry. With AbbVie and Gilead Sciences investing considerable sums in the firm’s CD47-based cancer therapies, investors are picking up the stock. CD47-based therapies target an innate checkpoint pathway employed by cancer cells to evade immune detection. Its lead drug candidates, TTI-621 and TTI-622, are CD47-targeting antibodies.

Thus far, Trillium’s ongoing dose-escalation studies for both are going well. Pharmaceutical titan Pfizer also took a $25 million position in Trillium. Analysts forecast to continue its growth momentum and deliver another 1,000% gains in a couple of years.

Potential triggers

Investors need to watch out for potential triggers. A resurgence in COVID-19 infections and failure of vaccine clinical trials are likely to destroy the market again. Election Day in the U.S. is coming, that political uncertainty will escalate as November draws near.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences.

More on Investing

edit Woman in skates works on laptop
Dividend Stocks

3 No-Brainer Stocks to Buy Under $30

These three stocks all offer a huge deal for investors looking for dividends, as well as growth that will last.

Read more »

Business man on stock market financial trade indicator background.
Tech Stocks

1 Growth Stock Down 50 Percent to Buy Right Now

There are plenty of growth stocks in the market worth considering, but Shopify (TSX:SHOP) looks like one of the best…

Read more »

You Should Know This
Dividend Stocks

How to Convert a $300 Monthly Investment Into $338 in Monthly Income

If you want a certain amount in monthly passive income, invest a similar amount today and leave the rest to…

Read more »

Increasing yield
Dividend Stocks

3 Income Stocks With Big Yields to Consider in April 2024

If you haven’t yet made your March investments, here are three income stocks to buy the dip and lock in…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

RRSP Investors: Don’t Miss Out on This Contribution Hack!

This hack has so many benefits for you -- not just when you put it in your RRSP but for…

Read more »

edit Sale sign, value, discount
Stocks for Beginners

These 3 Growth Stocks Are on Sale and Set to Surge

Some growth stocks are on sale right now that offer massive long-term potential for investors. Here's a trio to consider…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Young woman sat at laptop by a window
Dividend Stocks

3 Dividend Stocks Everyone Should Own for the Long Haul

For investors looking for top-tier dividend stocks to buy and hold for the long term, here are three of my…

Read more »